Preventive actions of a high dose of glucosamine on adjuvant arthritis in rats

Inflammation Research

Volumn 54, Issue 3, 2005, Pages 127-132

  Hua, J ^a   Suguro, S ^a,b   Hirano, S ^c   Sakamoto, K ^b   Nagaoka, I ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b Koyo Chemical Co Ltd   (Japan)

^c Mercian Cleantec Corporation   (Japan)

Author keywords

Adjuvant arthritis; Glucosamine; Nitric oxide; Prostaglandin E2; Synovial hyperplasia

Indexed keywords

FREUND ADJUVANT; GLUCOSAMINE; NITRIC OXIDE; PROSTAGLANDIN E2;

ADJUVANT ARTHRITIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARTILAGE DEGENERATION; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; HINDLIMB; HISTOPATHOLOGY; HYPERPLASIA; INFLAMMATORY CELL; MALE; NONHUMAN; OSTEOARTHRITIS; PAW EDEMA; RAT; RHEUMATOID ARTHRITIS; SYNOVIUM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FREUND'S ADJUVANT; GLUCOSAMINE; INFLAMMATION; MALE; NITRIC OXIDE; RATS; RATS, WISTAR; SYNOVIAL MEMBRANE; TIME FACTORS;

EID: 20044390083     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00011-004-1333-6     Document Type: Article

References (31)

1. Firestein GS. Etiology and pathogenesis of rheumatoid arthritis. In: Ruddy S, Harris JED, Sledge CB, Budd RC, Sergent JS, editors. Kelley's textbook of rheumatology. Vol. 2. Philadelphia: W.B. Saunders Company, 2001: 921-66.
2. Schuna AA, Megeff C. New drugs for the treatment of rheumatoid arthritis. Am J Health Syst Pharm 2000; 57: 225-34.
3. Santana-Sabagun E, Weisman MH. Nonsteroidal anti-inflammatory drugs. In: Ruddy S, Harris JED, Sledge CB, Budd RC, Sergent JS, editors. Kelly's textbook of rheumatology. Vol. 1. Philadelphia: W.B. Saunders Company, 2001: 799-822.
4. Newman NM, Ling RSM. Acetabular bone destruction related to non-steroidal anti-inflammatory drugs. Lancet 1985; 2: 11-4.
5. Anastassiades T, Chopra R, Law C, Wong E. In vitro suppression of transforming growth factor-β induced stimulation of glycosaminoglycan synthesis by acetylsalicylic acid and its reversal by misoprostol. J Rheumatol 1998; 25: 1962-7.
6. Crolle G, D'Este E. Glucosamine sulphate for the management of arthrosis: a controlled clinical investigation. Curr Med Res Opin 1980; 7: 104-9.
7. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002; 162: 2113-23.
8. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283: 1469-75.
9. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357: 251-6.
10. Fenton JI, Chlebek-Brown KA, Peters TL, Caron JP, Orth MW. Glucosamine HCl reduces equine articular cartilage degradation in explant culture. Osteoarthritis Cartilage 2000; 8: 258-65.
11. Oegema TR Jr, Deloria LB, Sandy JD, Hart DA. Effect of oral glucosamine on cartilage and meniscus in normal and chymopapain-injected knees of young rabbits. Arthritis Rheum 2002; 46: 2495-503.
12. Gouze JN, Bordji K, Gulberti S, Terlain B, Netter P, Magdalou J et al. Interleukin-1β down-regulates the expression of glucuronosyl-transferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1β-mediated effects in rat chondrocytes. Arthritis Rheum 2001; 44: 351-60.
13. Hua J, Sakamoto K, Nagaoka I. Inhibitory actions of glucosamine, a therapeutic agent for osteoarthritis, on the functions of neutrophils. J Leukoc Biol 2002; 71: 632-40.
14. Ma L, Rudert WA, Harnaha J, Wright M, Machen J, Lakomy R et al. Immunosuppressive effects of glucosamine. J Biol Chem 2002; 277: 39343-9.
15. Naik RS, Krishnegowda G, Gowda DC. Glucosamine inhibits inositol acylation of the glycosylphosphatidylinositol anchors in intraerythrocytic Plasmodium falciparum. J Biol Chem 2003; 278: 2036-42.
16. Mohr W, Wild A. Adjuvant arthritis. Arzneimitterfolschung 1976; 26: 1860-6.
17. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983; 16: 109-10.
18. Gryglewski RJ. Some experimental models for the study of inflammation and anti-inflammatory drugs. Agents Actions Suppl 1977: 17-23.
19. Hirano S, Wakazono K, Agata N, Mase T, Yamamoto R, Matsufuji M et al. Effects of cytogenin, a novel anti-arthritic agent, on type II collagen-induced arthritis in DBA/1J mice and adjuvant arthritis in Lewis rats. Int J Tissue React 1994; 16: 155-62.
20. Wood FD, Pearson CM, Tanaka A. Capacity of mycobacterial wax D and its subfractions to induce adjuvant arthritis in rats. Int Arch Allergy Appl Immunol 1969; 35: 456-67.
21. Jang D, Murrell GAC. Nitric oxide in arthritis. Free Radic Biol Med 1998; 24: 1511-9.
22. Setnikar I, Pacini MA, Revel L. Antiarthritic effects of glucosamine sulfate studied in animal models. Arzneimittelforschung 1991; 41: 542-5.
23. Houpt JB, McMillan R, Wein C, Paget-Dellio SD. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J Rheumatol 1999; 26: 2423-30.
24. Russell AI, McCarty MF. Glucosamine in osteoarthritis. Lancet 1999; 354: 1641.
25. Hua J, Suguro S, Iwabuchi K, Tsutsumi-Ishii Y, Sakamoto K, Nagaoka I. Glucosamine, a naturally occurring amino monosaccharide suppresses the ADP-mediated platelet activation in humans. Inflamm Res 2004; 53: 680-8.
26. Setnikar I, Giacchetti C, Zanolo G. Pharmacokinetics of glucosamine in the dog and in man. Arzneimittelforschung 1986; 36: 729-35.
27. Aghazadeh-Habashi A, Sattari S, Pasutto F, Jamali F. Single dose pharmacokinetics and bioavailability of glucosamine in the rat. J Pharm Pharm Sci 2002; 5: 181-4.
28. McInnes IB, Leung BP, Field M, Wei XQ, Huang FP, Sturrock RD et al. Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients. J Exp Med 1996; 184: 1519-24.
29. Crofford LJ, Wilder RL, Ristimaki AP, Sano H, Remmers EF, Epps HR et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1β, phorbol ester, and corticosteroids. J Clin Invest 1994; 93: 1095-101.
30. 2, nitric oxide and metalloproteases by chondrocytes and synoviocytes in osteoarthritis. Clin Exp Rheumatol 2004; 22: 293-9
31. th General Assembly and Scientific Meeting of Japan College of Rheumatology 2004; abstract: 298.